从拓宽独董提名渠道到特别代表人诉讼扩容，证监会17个案例解码投资者保护升级路径

Core Viewpoint - The article highlights the ongoing efforts by the China Securities Regulatory Commission (CSRC) to enhance investor protection through stricter regulations and innovative measures aimed at addressing capital market irregularities and safeguarding investor rights [1][2][3]. Regulatory Actions - In 2024, the CSRC investigated 739 cases of securities and futures violations, resulting in 592 penalties, a 10% increase year-on-year. The number of responsible parties penalized rose by 24% to 1,327, and 118 individuals were banned from the market, up 15% [1]. - The CSRC has implemented measures to address the long-standing issue of major shareholders misappropriating company funds, with companies facing delisting risks if they fail to return misappropriated funds in a timely manner [1][5]. Investor Protection Initiatives - The introduction of the special representative litigation system has been expanded, with successful applications in the Jin Tong Ling and Mei Shang Ecology cases in 2024, aimed at efficiently resolving collective disputes [6]. - The Investor Protection Center (IPC) has publicly nominated independent directors for listed companies, with the first successful case being First Pharmaceutical, where 99.99% of voting shares supported the nomination [3][4]. Legal Developments - The IPC's lawsuit against Tai'an Tui for the recovery of misappropriated funds resulted in a full recovery of 572 million yuan through a judicial mediation process, marking a significant achievement in shareholder litigation [4][5]. - The IPC's efforts led to the successful recovery of 5.34 billion yuan in misappropriated funds from *ST Xintong, which faced delisting risks due to non-compliance with fund recovery mandates [5]. Anti-Fraud Measures - A new anti-fraud mechanism has been established in collaboration with local police to combat investment-related scams, resulting in the prevention of 732 fraud cases and the recovery of 19.265 million yuan [7][8].